By Dean Seal
Vesicor Therapeutics has signed a deal to combine with special purpose acquisition company Black Hawk Acquisition.
The blank-check company said Monday that it has reached a business-combination agreement with Vesicor, a California biotechnology company.
Vesicor was founded in 2008 and focuses on the development of p53-based cancer therapeutics delivered through microvesicles.
The transaction, which has been approved by the boards of both companies, gives Vesicor a pre-money equity value of $70 million.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 28, 2025 18:33 ET (22:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。